Estramustine binding protein in primary tumours and metastases of malignant melanoma.

Article Details

Citation

Copy to clipboard

von Schoultz E, Carlstrom K, Henriksson R, Lagerlof B, Hansson J

Estramustine binding protein in primary tumours and metastases of malignant melanoma.

Melanoma Res. 1994 Dec;4(6):401-5.

PubMed ID

7703721 [ View in PubMed

]

Abstract

The presence of estramustine binding protein (EMBP), a 54 kD cytosolic glycoprotein, which is distinct from the estrogen receptor, was investigated in a pilot study of primary malignant melanomas and their metastases. In 11 primary melanomas EMBP was demonstrated by immunohistochemistry. The percentage of positive melanoma cells ranged between 11-91% with a mean of 57%. Radioimmunoassay on metastatic tissue revealed significant amounts of EMBP, with values ranging between 0.6-4.2 with a mean of 1.6 ng/mg protein. A high number of cells with a positive stain for EMBP in the primary tumours was significantly correlated to a short interval between diagnosis and the occurrence of metastases. Presence of EMBP in malignant melanoma may have prognostic significance and the role of hormone-linked cytostatic drugs in the treatment of this disease needs further investigation.

DrugBank Data that Cites this Article

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Estramustine	Estrogen receptor alpha	Protein	Humans	Yes	Agonist	Details